Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

• Published in: Diabetes care Vol. 42; no. 1; pp. 173 - 176
• Main Authors: Leiter, Lawrence A., Teoh, Hwee, Kallend, David, Wright, R. Scott, Landmesser, Ulf, Wijngaard, Peter L.J., Kastelein, John J.P., Ray, Kausik K.
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01.01.2019
• Subjects: Apolipoprotein B; Apolipoproteins B - blood; Arteriosclerosis; Atherosclerosis; Atherosclerosis - blood; Atherosclerosis - drug therapy; Cardiovascular disease; Cardiovascular diseases; Cholesterol; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Clinical trials; Diabetes; Diabetes mellitus; Diabetes Mellitus - blood; Diabetes Mellitus - drug therapy; Dose-Response Relationship, Drug; Dyslipidemia; Dyslipidemias - blood; Dyslipidemias - drug therapy; Evidence-based medicine; Female; Health risks; High density lipoprotein; Humans; Kexin; Lipids; Low density lipoprotein; Male; Metabolic disorders; Middle Aged; Proprotein Convertase 9 - blood; Research design; Risk Factors; RNA, Small Interfering - pharmacology; siRNA; Subtilisin

To evaluate the efficacy and safety of inclisiran by diabetes status. ORION-1 (ClinicalTrials.gov, NCT02597127) randomized 501 subjects with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalents and high LDL cholesterol (LDL-C), despite maximally tolerated LDL-C-lowering therapies...